CEL-SCI Home Page
preload preload

Press Releases

Corporate Presentations

Press Releases

August 3, 2015
NEW STORY CEL-SCI Reports Record Monthly Patient Enrollment in July for Its Phase 3 Head and Neck Cancer Trial

July 20, 2015
NEW STORY CEL-SCI Expands Its Phase I Study For Treatment of Anal Warts in HIV/HPV Co-Infected Patients with Addition of 2nd Site at University of California San Francisco

July 1, 2015
NEW STORY CEL-SCI Reports June Patient Enrollment in Its Phase 3 Head and Neck Cancer Trial

June 16, 2015
NEW STORY CEL-SCI to Present at the 2015 Bio International Convention

June 8, 2015
NEW STORY CEL-SCI is Cleared to Start Patient Enrollment for Its Phase 3 Cancer Immunotherapy Trial in Thailand

June 1, 2015
NEW STORY CEL-SCI Reports May Patient Enrollment in Its Phase 3 Head and Neck Cancer Trial

May 29, 2015
NEW STORY CEL-SCI Announces Closing of Public Offering for Gross Proceeds of $16 Million

May 27, 2015
NEW STORY CEL-SCI to Present at the 2015 Marcum MicroCap Conference

May 22, 2015
NEW STORY CEL-SCI Prices Up To $16 Million Public Offering of Common Stock and Warrants

May 21, 2015
NEW STORY CEL-SCI Announces Proposed Public Offering of Common Stock and Warrants

May 13, 2015
NEW STORY CEL-SCI Receives Authorization to Conduct Its Phase 3 Multikine Trial in Italy

May 11, 2015
NEW STORY CEL-SCI Receives Authorization to Conduct Its Phase 3 Multikine Trial in Spain

May 8, 2015
NEW STORY CEL-SCI Corporation Reports Second Quarter Fiscal Year 2015 Financial Results

May 1, 2015
NEW STORY CEL-SCI Reports 4th Consecutive Month of Record Patient Enrollment in 2015 for Its Phase III Head and Neck Cancer Trial

April 13, 2015
NEW STORY UK's Aintree University Hospital Joins CEL-SCI's Phase III Head and Neck Cancer Trial

February 6, 2015
CEL-SCI Corporation Reports First Quarter 2015 Financial Results

February 5, 2015
CEL-SCI to Present At 17th Annual BIO CEO & Investor Conference

January 5, 2015
CEL-SCI's 2014 Patient Enrollment Increases Eight-Fold Over 2013 in Its Phase III Head and Neck Cancer Trial

December 23, 2014
CEL-SCI Reports Fiscal 2014 Financial Results and Clinical & Corporate Developments

December 8, 2014
CEL-SCI Expands Its Pivotal Phase III Immunotherapy Head and Neck Cancer Trial with Addition of 7 More Clinical Sites

September 29, 2014
CEL-SCI & U.S. Navy Administer Multikine to First Volunteer Patient in Phase I Clinical Trial for Treatment of Anal Warts in HIV/HPV Co-Infected Patients

July 15, 2014
CEL-SCI Receives $225,000 NIH Research Grant to Develop Rheumatoid Arthritis Treatment

July 11, 2014
CEL-SCI Presents Rheumatoid Arthritis Data at the 12th Vaccines Research & Development: All Things Considered Conference

 

ADDITIONAL RELEASES
View All Corporate Press Releases


Phase III Clinical Trial Monthly Enrollment Chart

Number of Patients Enrolled per month since the transfer to the new CROs.

Phase III Enrollment Chart


 

THE CEL-SCI STORY